XTX Topco’s Pacira BioSciences PCRX Stock Holding History

XTX Topco’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.03M	Sell	40,525 -50,589	-56%	-$1.2M	0.01%	1763
2026 Q1	$2.06M	Buy	91,114 +8,208	+10%	+$182K	0.04%	815
2025 Q4	$2.15M	Buy	+82,906	New	+$1.97M	0.06%	531
2025 Q2	–	Sell	-27,133	Closed	-$674K	–	2966
2025 Q1	$674K	Sell	27,133 -605	-2%	-$14.5K	0.03%	807
2024 Q4	$523K	Buy	+27,738	New	+$487K	0.04%	736
2024 Q3	–	Sell	-9,222	Closed	-$264K	–	2469
2024 Q2	$264K	Buy	9,222 +88	+1%	+$2.5K	0.02%	1047
2024 Q1	$267K	Buy	+9,134	New	+$281K	0.04%	950
2023 Q4	–	Sell	-13,588	Closed	-$417K	–	1983
2023 Q3	$417K	Buy	13,588 +5,557	+69%	+$200K	0.07%	505
2023 Q2	$322K	Buy	+8,031	New	+$332K	0.06%	669
2023 Q1	–	Sell	-17,522	Closed	-$677K	–	1564
2022 Q4	$677K	Buy	+17,522	New	+$852K	0.14%	187
2021 Q2	–	Sell	-2,886	Closed	-$202K	–	1025
2021 Q1	$202K	Buy	+2,886	New	+$206K	0.1%	497

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

XTX Topco's PCRX Position: Q2 2026 in Review

XTX Topco reduced its Pacira BioSciences (PCRX) stake by 56% in Q2 2026, selling an estimated $1.2M and leaving 40,525 shares worth $1.03M. The position accounts for 0.01% of the portfolio, ranked #1763.

XTX Topco first reported a position in PCRX in Q1 2021 and has held it in 11 quarters since. The position peaked at $2.15M in Q4 2025. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

XTX Topco held 40,525 shares of Pacira BioSciences worth $1.03M as of Q2 2026.
XTX Topco sold 50,589 Pacira BioSciences shares in Q2 2026, an estimated $1.2M.
Pacira BioSciences made up 0.01% of XTX Topco's portfolio in Q2 2026, its #1763 holding.
XTX Topco first reported a position in Pacira BioSciences in Q1 2021 and has held it in 11 quarters since.
XTX Topco's Pacira BioSciences position peaked at $2.15M in Q4 2025.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.